Halberd Corp's TBI Mitigation Nasal Spray Shows Promising Phase II Results

Halberd Corporation, which trades on the OTC-PINK under the symbol "HALB," has reported promising results from Phase II tests of its Tri-Ax™ nasal spray at Mississippi State University (MSU). This nasal spray is designed to reduce the effects of traumatic brain injury (TBI) after head trauma. Dr. Russell Carr, the Principal Investigator for the project, highlighted that early Phase II studies aimed to evaluate the effectiveness of the Tri-Ax™ nasal spray in yielding positive outcomes when administered shortly after a TBI event. One of the primary focuses was on behavioral function, which is often significantly affected by TBI.

Dr. Carr further explained that preliminary data indicate that higher impact forces result in noticeable changes in motor activity levels. More importantly, when Tri-Ax™ was administered one hour after a high-impact force, the TBI-induced changes in motor activity showed significant improvement. These findings suggest that Tri-Ax™ offers therapeutic benefits if given promptly following an injury.

William A. Hartman, Chairman, President, and CEO of Halberd, expressed optimism that the positive results from Phase II testing would underline the unique advantages of their patent-pending nasal spray in preventing neurodegeneration after head trauma. He added that potential applications for the nasal spray span a wide range, including military and civilian contact sports, law enforcement, hospitals, and emergency response units dealing with incidents like automobile accidents and falls. If ongoing tests continue to support initial findings, the market potential for this product is substantial.

The encouraging results also highlight the potential for point of injury (POI) care. This novel TBI therapeutic could be administered by a companion or self-administered using an auto-nasal injector, which is currently being developed in collaboration with Halberd's partner, Athena GTX.

Mississippi State University's College of Veterinary Medicine (MSU CVM), established in 1974, houses six locations that serve all 82 counties in Mississippi and the broader Southeastern United States. The main campus in Starkville features the Wise Center, which is home to the Animal Health Center, the primary teaching hospital. The MSU CVM Department of Comparative Biomedical Sciences covers essential scientific disciplines crucial for veterinary education, demonstrating a strong commitment to ethical animal treatment.

Athena GTX, Inc., a certified Department of Defense small business headquartered in Johnston, Iowa, focuses on developing wearable and highly mobile, wirelessly connected monitoring technologies. These innovations are aimed at meeting the unmet needs of first responders globally by connecting patients and providers through wireless monitoring systems.

Halberd Corporation, a publicly traded company on the OTC Market, fully complies with OTC Market reporting regulations. Following a restructuring in April 2020, Halberd acquired exclusive global rights to three granted patents and submitted 22 related provisional, PCT, or utility patent applications. This strategic move aims to increase the company's value for shareholders and attract potential development partners.